Novo Nordisk on track for FY2003

Related tags Novo nordisk Growth hormone

Danish chemical group Novo Nordisk will likely deliver a
'lacklustre' set of results for the first nine months of the year
but strong enough to put the company on track to deliver its
guidance of 'low single-digit EBIT growth' on a reported basis for
the year, predicted Goldman Sachs.

Danish chemical group Novo Nordisk - with a market capitalisation of DK72.0bn - will likely deliver a 'lacklustre' set of results for the first nine months of the year but strong enough to put the company on track to deliver its guidance of 'low single-digit EBIT growth' on a reported basis for the year, predicted Goldman Sachs.

In a research report released this week Goldman Sachs said it expects the market to focus on the progress of Levemir and NovoSeven rather than on Novo's operational performance.

"We only expect an updateon the US launch of Levemir with Novo's full year results on 4 February next year, after the company has met with the FDA and clarified the FDA's additional requirements for Levemir,"​ said the analysts. With regards to NovoSeven, Goldman Sachs believes that the 280-patient trauma trial has been completed and that an announcement is possible by the year-end as the data is currently being analysed.

However, we believe that it is more likely that the results of this trauma trial will be presented with Novo's full year results in February 2003,"​ added the analysts.

"Despite the forecast of above-average 13 per cent EPS growth in 2002-2007 period, Novo trades at a 8 per cent discount tothe Pan-European drug sector on 2004 P/Es and at a 16 per cent discount on 2004 EV/EBITDA. We believe this is inappropriate and reiterates our Outperform rating on the stock within an Attractive sector coverage view."

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars